Alterity Therapeutics Secures FDA Nod for Single Phase 3 Trial in Multiple System Atrophy

FDA Endorsement Clears Regulatory Pathway for ATH434

Alterity Therapeutics (ASX:ATH, NASDAQ: ATHE) has achieved a pivotal regulatory milestone with the U.S. Food and Drug Administration (FDA) confirming a clear registrational pathway for its lead drug candidate, ATH434, targeting Multiple System Atrophy (MSA). The FDA agreed that a single pivotal Phase 3 trial, supplemented by confirmatory evidence from prior Phase 2 data, could support a New Drug Application (NDA) approval for this rare, rapidly progressive neurodegenerative disease with no approved therapies.

The Phase 3 trial is designed to enrol approximately 200 patients who will be randomized 1:1 to receive ATH434 50 mg or placebo twice daily over 12 months. The FDA has agreed on key trial elements including study population, treatment regimen, and the primary endpoint, the 11-item Unified Multiple System Atrophy Rating Scale (UMSARS) Part I. Secondary endpoints will evaluate other critical areas of impairment, while an open-label extension is planned to continue treatment and bolster the safety database.

Clinical Evidence and Manufacturing Progress

Alterity’s Phase 2 clinical trial data has demonstrated clinically meaningful efficacy, providing the confirmatory evidence the FDA requires. The company has also secured positive feedback on the chemistry, manufacturing, and control (CMC) aspects of the Phase 3 program, successfully producing the first registration batch of ATH434 for the pivotal trial.

Scientific engagement remains a cornerstone of Alterity’s strategy, with recent presentations highlighting the drug’s impact on slowing functional decline and validating quantitative susceptibility mapping (QSM) of brain iron as a biomarker for MSA. These findings were disseminated at major neurology conferences and through peer-reviewed publications, reinforcing ATH434’s mechanism as an iron chaperone and its potential to modify disease progression.

Financial Position and Corporate Developments

Alterity closed the quarter with a cash balance of A$37.3 million, following operating outflows of A$7.72 million. Subsequent to quarter-end, the company received a A$3.98 million Australian R&D tax incentive refund, further bolstering its financial flexibility. The company also completed a 1-for-50 share consolidation in May 2026, a move aimed at optimising its capital structure.

Governance was strengthened with the appointment of Ann Cunningham as an independent Non-Executive Director, bringing global commercial and strategic expertise as Alterity transitions toward late-stage clinical development.

Strategic Funding and Partnership Exploration

With Phase 3 trial activities on track to commence by year-end 2026, Alterity is actively exploring strategic funding and partnership opportunities. The company is conducting a structured evaluation process with external advisers, aiming to secure the necessary resources to advance ATH434 while maximising long-term shareholder value. This approach maintains strategic flexibility amid a competitive biotech landscape.